Health Care & Life Sciences » Biotechnology | Microbix Biosystems Inc.

Microbix Biosystems Inc. | Cash Flow

Fiscal year is October-September. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
1.40
169.00
614.00
748.40
3,780.10
8,621.60
Depreciation, Depletion & Amortization
419.20
403.30
418.40
413.70
510.20
690.10
Other Funds
100.00
-
-
-
-
8,599.20
Funds from Operations
458.80
360.80
1,235.60
1,474.60
194.80
667.70
Changes in Working Capital
30.50
1,531.70
640.20
561.30
491.90
1,204.70
Net Operating Cash Flow
428.40
1,170.80
595.40
913.30
297.00
537
Capital Expenditures
226.50
3,380.20
4,842.00
1,641.10
640.80
Sale of Fixed Assets & Businesses
232.70
-
-
-
-
Net Investing Cash Flow
6.30
3,130.20
4,842.00
1,641.10
640.80
Issuance/Reduction of Debt, Net
607.40
1,374.50
1,163.20
97.40
392.70
Net Financing Cash Flow
416.50
4,588.30
3,803.40
629.10
392.70
Net Change in Cash
31.60
287.30
443.20
98.80
49.00
Free Cash Flow
201.90
4,551.00
2,843.20
210.70
115.00
Deferred Taxes & Investment Tax Credit
-
265.00
265.00
600.00
450.00
-
Other Sources
-
250.00
-
-
-
Change in Capital Stock
290.90
3,213.80
2,640.30
531.70
-
Exchange Rate Effect
13.50
-
-
-
-

About Microbix Biosystems

View Profile
Address
265 Watline Avenue
Mississauga Ontario L4Z 1P3
Canada
Employees -
Website http://www.microbix.com
Updated 07/08/2019
Microbix Biosystems, Inc. engages in the manufacture of viral and bacterial antigens and reagents for the global diagnostics industry. Its biological solutions include products for human health applications in the vaccine, therapeutic and diagnostic markets, and a product for the worldwide animal reproduction market. Its pipeline of technologies and products include LumiSort, semen sexing technology for the livestock industries; and Kinlytic, a thrombolytic drug for life-threatening blood clots.